Evidence map›Paper›PMID 41209299›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Metabolic engineering of

Ye Chan Kim, Won Yoon Hwan Choi, Eun-Jung Kim, Byung-Gee Kim, Hyungdon Yun

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ye Chan Kim *Department of Systems Biotechnology, Konkuk University, Seoul, Republic of Korea.
Won Yoon Hwan Choi *Department of Systems Biotechnology, Konkuk University, Seoul, Republic of Korea.
Eun-Jung KimEGC Therapeutics, Inc., Seoul, Republic of Korea.
Byung-Gee KimSchool of Chemical and Biological Engineering, Seoul National University, Seoul, Republic of Korea.
Hyungdon YunDepartment of Systems Biotechnology, Konkuk University, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Medium- to long-chain α, ω-diols are valuable building blocks for polyesters and polyurethanes, yet their microbial synthesis from inexpensive alkane feedstocks remains largely undeveloped. The oleaginous yeast Yarrowia lipolytica offers advantages over bacterial systems such as Escherichia coli for alkane conversion due to its inherent capacity to metabolize hydrophobic substrates. Methods: To enable de novo α, ω-diol production from alkanes, we used CRISPR-Cas9 to delete ten genes involved in fatty alcohol oxidation (including FADH, ADH1 -8, and FAO1) and four genes linked to fatty aldehyde oxidation (FALDH1 -4). This generated the strain YALI17, with reduced over-oxidation activity. Further metabolic enhancement was achieved by overexpressing alkane hydroxylase genes, particularly ALK1. Fermentation performance was evaluated under controlled pH conditions using n-dodecane as the substrate. Results: The engineered strain YALI17 produced 1,12-dodecanediol at 0.72 mM from 50 mM n-dodecane -a 14-fold increase relative to the parental strain. ALK1 overexpression in YALI17 further raised production to 1.45 mM, and automated pH-controlled biotransformation achieved 3.2 mM. Discussion: This study demonstrates the first successful biotransformation of medium- to long-chain α, ω-diols directly from alkanes in yeast. The rational pathway design and oxidation-pathway blocking highlight Y. lipolytica as a promising cell factory for alkane-based biomanufacturing and lay the groundwork for sustainable production of high-value diol precursors through targeted metabolic engineering.

Indexed as

alkanesCRISPR-Cas9diolshydroxylationmetabolic engineeringyarrowia lipolytica

Identifiers

PMID41209299
PMCPMC12588895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.